非小细胞肺癌脑转移第一线Camrelizumab与安慰剂联合化疗加放疗或不加放疗的比较：CTONG 2003随机安慰剂对照试验

文章预览

SCI 26 February 2025 First-Line Camrelizumab versus Placebo Plus Chemotherapy with or without Radiotherapy for Brain Metastases in Non-Small-Cell Lung Cancer: The CTONG 2003 Randomized Placebo-Controlled Trial (Journal of Thoracic Oncology; if=21) Li YS, Yu Q, Bu Q, Lin L, Ning F, Zhao Y, Wu G, Lin G, Zang A, Sun H, Huang J, Tu HY, Ma S, Zhou C, Liu A, Wang C, Yao Y, Han G, Zhao J, Zhou Q, Yan HH, Liu SM, Zheng MM, Lv J, Cheng F, Chen Z, Zhong WZ, Pan Y, Yang JJ, Wu YL.  Correspondence: syylwu@live.cn Introduction 引言 Retrospective studies have indicated potential benefits of immunotherapy for brain metastases (BM) in non-small-cell lung cancer (NSCLC). CTONG 2003 is the first randomized controlled trial to evaluate camrelizumab for untreated BM of NSCLC. 回顾性研究表明，免疫疗法对非小细胞肺癌（NSCLC）脑转移（BM）的潜在益处。CTONG 2003是第一个评估camrelizumab治疗非小细胞肺癌未经治疗骨髓的随机对照试验。 Methods 方法 CTO ………………………………